Requests for meetings with FDA staff about products in development should include pertinent details about pediatric study plans, human factors engineering plans and combination product information; new guidance documents on formal meetings under PDUFA VI and communications with IND sponsors operationalize user fee program commitments and will promote earlier, more thorough engagement, agency says.
The US FDA wants sponsors to provide more information about drugs under development when they request a formal meeting with the agency pursuant to the Prescription Drug User Fee Act (PDUFA VI).
Requests for Type A, B or C meetings should now include information, if applicable, about pediatric study plans, human factors...